The role of the VEGF-C/VEGFR-3 axis in cancer progression

J. L. Su, Chia-Jui Yen, Pai-Sheng Chen, S. E. Chuang, C. C. Hong, I. H. Kuo, H. Y. Chen, M. C. Hung, M. L. Kuo

Research output: Contribution to journalShort survey

167 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) receptor 3 (VEGFR-3) (also called VEGFR-3) is activated by its specific ligand, VEGF-C, which promotes cancer progression. The VEGF-C/VEGFR-3 axis is expressed not only by lymphatic endothelial cells but also by a variety of human tumour cells. Activation of the VEGF-C/VEGFR-3 axis in lymphatic endothelial cells can facilitate metastasis by increasing the formation of lymphatic vessels (lymphangiogenesis) within and around tumours. The VEGF-C/VEGFR-3 axis plays a critical role in leukaemic cell proliferation, survival, and resistance to chemotherapy. Moreover, activation of the VEGF-C/VEGFR-3 axis in several types of solid tumours enhances cancer cell mobility and invasion capabilities, promoting cancer cell metastasis. In this review, we discuss the novel function and molecular mechanism of the VEGF-C/VEGFR-3 axis in cancer progression.

Original languageEnglish
Pages (from-to)541-545
Number of pages5
JournalBritish Journal of Cancer
Volume96
Issue number4
DOIs
Publication statusPublished - 2007 Feb 26

Fingerprint

Vascular Endothelial Growth Factor C
Neoplasms
Endothelial Cells
Vascular Endothelial Growth Factor Receptor-3
Lymphangiogenesis
Neoplasm Metastasis
Lymphatic Vessels
human FLT4 protein
Cell Survival
Cell Proliferation
Ligands
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Su, J. L. ; Yen, Chia-Jui ; Chen, Pai-Sheng ; Chuang, S. E. ; Hong, C. C. ; Kuo, I. H. ; Chen, H. Y. ; Hung, M. C. ; Kuo, M. L. / The role of the VEGF-C/VEGFR-3 axis in cancer progression. In: British Journal of Cancer. 2007 ; Vol. 96, No. 4. pp. 541-545.
@article{54db1195257f40eca78ba4b18b11b8a3,
title = "The role of the VEGF-C/VEGFR-3 axis in cancer progression",
abstract = "Vascular endothelial growth factor (VEGF) receptor 3 (VEGFR-3) (also called VEGFR-3) is activated by its specific ligand, VEGF-C, which promotes cancer progression. The VEGF-C/VEGFR-3 axis is expressed not only by lymphatic endothelial cells but also by a variety of human tumour cells. Activation of the VEGF-C/VEGFR-3 axis in lymphatic endothelial cells can facilitate metastasis by increasing the formation of lymphatic vessels (lymphangiogenesis) within and around tumours. The VEGF-C/VEGFR-3 axis plays a critical role in leukaemic cell proliferation, survival, and resistance to chemotherapy. Moreover, activation of the VEGF-C/VEGFR-3 axis in several types of solid tumours enhances cancer cell mobility and invasion capabilities, promoting cancer cell metastasis. In this review, we discuss the novel function and molecular mechanism of the VEGF-C/VEGFR-3 axis in cancer progression.",
author = "Su, {J. L.} and Chia-Jui Yen and Pai-Sheng Chen and Chuang, {S. E.} and Hong, {C. C.} and Kuo, {I. H.} and Chen, {H. Y.} and Hung, {M. C.} and Kuo, {M. L.}",
year = "2007",
month = "2",
day = "26",
doi = "10.1038/sj.bjc.6603487",
language = "English",
volume = "96",
pages = "541--545",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

Su, JL, Yen, C-J, Chen, P-S, Chuang, SE, Hong, CC, Kuo, IH, Chen, HY, Hung, MC & Kuo, ML 2007, 'The role of the VEGF-C/VEGFR-3 axis in cancer progression', British Journal of Cancer, vol. 96, no. 4, pp. 541-545. https://doi.org/10.1038/sj.bjc.6603487

The role of the VEGF-C/VEGFR-3 axis in cancer progression. / Su, J. L.; Yen, Chia-Jui; Chen, Pai-Sheng; Chuang, S. E.; Hong, C. C.; Kuo, I. H.; Chen, H. Y.; Hung, M. C.; Kuo, M. L.

In: British Journal of Cancer, Vol. 96, No. 4, 26.02.2007, p. 541-545.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - The role of the VEGF-C/VEGFR-3 axis in cancer progression

AU - Su, J. L.

AU - Yen, Chia-Jui

AU - Chen, Pai-Sheng

AU - Chuang, S. E.

AU - Hong, C. C.

AU - Kuo, I. H.

AU - Chen, H. Y.

AU - Hung, M. C.

AU - Kuo, M. L.

PY - 2007/2/26

Y1 - 2007/2/26

N2 - Vascular endothelial growth factor (VEGF) receptor 3 (VEGFR-3) (also called VEGFR-3) is activated by its specific ligand, VEGF-C, which promotes cancer progression. The VEGF-C/VEGFR-3 axis is expressed not only by lymphatic endothelial cells but also by a variety of human tumour cells. Activation of the VEGF-C/VEGFR-3 axis in lymphatic endothelial cells can facilitate metastasis by increasing the formation of lymphatic vessels (lymphangiogenesis) within and around tumours. The VEGF-C/VEGFR-3 axis plays a critical role in leukaemic cell proliferation, survival, and resistance to chemotherapy. Moreover, activation of the VEGF-C/VEGFR-3 axis in several types of solid tumours enhances cancer cell mobility and invasion capabilities, promoting cancer cell metastasis. In this review, we discuss the novel function and molecular mechanism of the VEGF-C/VEGFR-3 axis in cancer progression.

AB - Vascular endothelial growth factor (VEGF) receptor 3 (VEGFR-3) (also called VEGFR-3) is activated by its specific ligand, VEGF-C, which promotes cancer progression. The VEGF-C/VEGFR-3 axis is expressed not only by lymphatic endothelial cells but also by a variety of human tumour cells. Activation of the VEGF-C/VEGFR-3 axis in lymphatic endothelial cells can facilitate metastasis by increasing the formation of lymphatic vessels (lymphangiogenesis) within and around tumours. The VEGF-C/VEGFR-3 axis plays a critical role in leukaemic cell proliferation, survival, and resistance to chemotherapy. Moreover, activation of the VEGF-C/VEGFR-3 axis in several types of solid tumours enhances cancer cell mobility and invasion capabilities, promoting cancer cell metastasis. In this review, we discuss the novel function and molecular mechanism of the VEGF-C/VEGFR-3 axis in cancer progression.

UR - http://www.scopus.com/inward/record.url?scp=33847198622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847198622&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6603487

DO - 10.1038/sj.bjc.6603487

M3 - Short survey

VL - 96

SP - 541

EP - 545

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -